Adverum Biotechnologies (NASDAQ:ADVM) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel ... American Banking News, 1 month ago
Equities Research Analysts Updated EPS Estimates for May, 5th (ACAD, AGQ, AIDIF, AIG, ALD, ANTO, ATVI, AXL, BA, BABA) - American Banking News - Earnings, 1 month ago
on your WebpageAdd Widget >Get your members hooked!